FIELD: chemistry.
SUBSTANCE: invention refers to compounds of formula (I).
(I).
EFFECT: technical result is obtaining novel compounds suitable as PDE1 inhibitors which can be used as a medicament, particularly for treating neurodegenerative disorders and psychiatric disorders.
15 cl, 1 tbl, 100 ex
Title | Year | Author | Number |
---|---|---|---|
8-METHYL-1-PHENYLIMIDAZO[1,5-a]PYRAZINE COMPOUNDS | 2011 |
|
RU2560162C2 |
NEW IMIDAZO[4,5-c]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS | 2018 |
|
RU2773516C2 |
IMIDAZOPYRAZINES | 2012 |
|
RU2600327C2 |
PYRAZINE COMPOUNDS AND THEIR USE | 2019 |
|
RU2809631C2 |
HETEROARYL COMPOUNDS, COMPOSITIONS CONTAINING THEM AND METHODS OF TREATING WITH USE OF SUCH COMPOUNDS | 2007 |
|
RU2478635C2 |
PYRAZOLO [3,4-C] PYRIDINES AND METHODS OF APPLICATION THEREOF | 2012 |
|
RU2638116C2 |
NEW DERIVATIVES OF IMIDAZO [4,5-C] QUINOLINES AND IMIDAZO [4,5-C] [1,5] NAPHTHYRIDINES AS LRRK2 INHIBITORS | 2016 |
|
RU2722149C1 |
HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | 2018 |
|
RU2797822C2 |
IMIDAZOPYRIDINE COMPOUNDS AS PAD INHIBITORS | 2018 |
|
RU2782743C2 |
PHENOXYPYRIDINYLAMIDE DERIVATIVES, AND THEIR USE IN TREATMENT OF PDE4-MEDIATED DISEASE STATES | 2009 |
|
RU2509077C2 |
Authors
Dates
2020-01-27—Published
2016-04-29—Filed